Drug name | Company | Therapy area | Year |
Secukinumab (Cosentyx) | Novartis International AG | Excessive immune response/autoimmunity | 2015 |
Veruprevir, ritonavir, ombitasvir and dasabuvir (Viekira Pak) | AbbVie Inc. | Respiratory disease | 2015 |
Idelalisib (Zydelig) | Gilead Sciences Inc. | Oncology | 2014 |
Sofosbuvir (Sovaldi) | Gilead Sciences Inc. | Infectious disease | 2014 |
Vilanterol plus umeclidinium (Anoro Ellipta) | GlaxoSmithKline plc, Theravance Biopharma Inc. | Respiratory disease | 2014 |
Apremilast (Otezla) | Celgene Corporation | Excessive immune response/autoimmunity | 2013 |
Fluticasone furoate plus vilanterol trifenatate (Relovair) | GlaxoSmithKline plc, Theravance Biopharma Inc. | Respiratory disease | 2013 |
Icosapent ethyl ester (Vascepa) | Amarin Corporation plc | Cardiovascular disease | 2013 |
Pomalidomide (Pomalyst) | Celgene Corporation | Oncology | 2013 |
Trastuzumab emtansine (T-DM1) | Roche | Oncology | 2013 |
Umeclidinium plus vilanterol (Zephyr) | GlaxoSmithKline plc, Theravance Biopharma Inc. | Respiratory disease | 2013 |